Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyHMSA Global Oncology Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    ModifiedHawaii Medical Service Association (HMSA)Policy N/A

    Global Oncology

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs precertification and coverage of oncology drugs prescribed as single agents or regimens under the medical benefit, including oral drugs used as part of an oncology regimen. It applies to HMSA HMO, PPO, QUEST, and Medicare Advantage members, subject to member contract exclusions and applicable Medicare coverage rules.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyGlobal Oncology
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJune 12, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for one or more agents within a prescribed oncology regimen.
    SourceLink
    POLICY UPDATE CHANGES

    Evdi and Decnupaz were added to the medical benefit drug list effective June 12, 2026.

    Keytruda Qlex was added to the medical benefit drug list on May 18, 2026.

    Rybrevant Faspro and Vykoura were added to the medical benefit drug list on March 13, 2026.

    Alimta was removed and Favlyxa was added on April 14, 2026.

    Lymphir was added to the medical benefit drug list on December 23, 2025.

    The document history records removal of Imaavy, Aliqopa, and other previously listed products during 2025.

    Several products were removed because they were oral therapies, indicating that the medical benefit list focuses on applicable non-oral administration products.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial authorization period
    12 monthsPotential reauthorization period
    3Initial authorization pathways
    RequiredUtilization management
    No progressionReauthorization disease status
    4Product lines

    Coverage Criteria

    Initial Therapy

    Authorization for 6 months may be granted when the member is prescribed a single agent or regimen supported by at least one of the following:

    ONE of the following

    • FDA-approved indication
    • National Comprehensive Cancer Network (NCCN) I or IIA recommendation
    • HMSA Criteria Exception (Commercial and Quest) or Off-Label Drug Use (Medicare Part B) policy

    Continuation Therapy — Reauthorization

    Approval for an additional 12 months may be granted for members previously approved for the drug or regimen by HMSA or HMSA's Pharmacy Benefit Manager when documentation shows benefit from treatment and all of the following are met:

    ALL of the following

    • A current oncology note documents the patient's response to treatment showing no progression of disease
    • Current imaging studies and other objective measures show no progression of disease when compared with previous results

    Continuation Therapy — No Previous Authorization

    All members, including new members and members currently receiving treatment without prior authorization, must meet the criteria for initial approval in Section C.

    Meet all Initial Therapy criteria in Section C.

    Precertification is required for one or more agents within a prescribed oncology regimen. The entire regimen will be covered when all drugs within the regimen are prescribed in accordance with the guidelines set forth in this policy, provided the member has no exclusions to the prescribed therapy. This policy applies to drugs covered under the medical benefit listed in the Appendix. Oral drugs will also be reviewed when prescribed as part of the oncology regimen.

    For Medicare Advantage members, a National Coverage Determination (NCD) or Local Coverage Determination (LCD) may apply. Medical benefit drugs marked with an asterisk (*) in the Appendix are not covered under Medicare Part B. Medical benefit drugs marked with a dagger (†) do not require prior authorization under Medicare Part B.

    Previously added products were removed because they are oral therapies.

    The purpose of this Medical Policy is to provide a guide to coverage and is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

    Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

    This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), generally accepted standards of medical practice, and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA or HMSA's Pharmacy Benefit Manager's determination as to medical necessity in a given case, the physician may request that HMSA reconsider application of the medical necessity criteria to the case in light of supporting documentation.

    Coding and Medicare References

    Medicare Advantage NCD referencesmixed
    NCD 110.17National Coverage Determination for Anti-Cancer Chemotherapy for Colorectal Cancer
    NCD 110.22National Coverage Determination for Autologous Cellular Immunotherapy Treatment

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Precertification Required for Oncology Regimens

    Precertification is required for one or more agents within a prescribed oncology regimen. The entire regimen may be covered when all drugs are prescribed according to this policy and the member has no exclusions to the therapy.

    • Submit the precertification request through the HMSA medical specialty drug policy process.
    • Precertification applies to the prescribed oncology regimen, including one or more agents.
    Prior Authorization

    Drugs Subject to Review

    HMSA reviews drugs covered under the medical benefit that are listed in the Appendix. Oral drugs are also subject to review when prescribed as part of an oncology regimen.

    • Medical-benefit drugs listed in the Appendix
    • Oral drugs prescribed as part of an oncology regimen

    Policy Scope

    This is a broad oncology policy addressing single-agent and multi-drug cancer regimens rather than a single tumor type or drug. Coverage is evaluated for medical-benefit drugs and regimens based on an FDA-approved indication, an applicable NCCN category I or IIA recommendation, or the relevant HMSA exception or Medicare Part B off-label policy.

    Key Definitions

    NCCN I or IIA recommendation
    DefinitionA recommendation category identified by the National Comprehensive Cancer Network as category I or IIA.
    Reauthorization
    DefinitionA request for additional authorization after an initial approval by HMSA or HMSA's Pharmacy Benefit Manager for the drug or regimen.

    Covered Oncology Regimens

    RegimenCoverageQualifying basisConditions
    Prescribed single agent or oncology regimenCoveredFDA-approved indication; NCCN category I or IIA recommendation; or HMSA Criteria Exception policy for Commercial and QUEST members or Off-Label Drug Use policy for Medicare Part BPrecertification is required for one or more agents. All drugs in the regimen must be prescribed in accordance with the policy, and no member exclusion may apply.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyGlobal Oncology
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateJune 12, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for one or more agents within a prescribed oncology regimen.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Medicare ReferencesAuthorization, Documentation, and Denial RisksPolicy ScopeKey DefinitionsCovered Oncology Regimens
    Billing Rule

    Medicare Advantage Program Rules

    For Medicare Advantage members, coverage is governed by any applicable National Coverage Determination (NCD) or Local Coverage Determination (LCD). Appendix markings also affect Medicare Part B coverage and prior authorization requirements.

    • Avastin and Erbitux: NCD for Anti-Cancer Chemotherapy for Colorectal Cancer (110.17) may apply.
    • Provenge: NCD for Autologous Cellular Immunotherapy Treatment (110.22) may apply, including the listed compendial use for biochemical relapse of androgen-dependent (castration-naïve) prostate cancer.
    • Medical-benefit drugs marked with an asterisk (*) are not covered under Medicare Part B.
    • Medical-benefit drugs marked with a dagger (†) do not require prior authorization under Medicare Part B.
    Documentation Required

    Support the Initial Diagnosis

    For initial therapy, submit chart notes or other clinical information that supports the member’s diagnosis and the requested treatment.

    • Required for initial therapy requests
    Documentation Required

    Document Response to Treatment

    For continuation therapy, submit documentation demonstrating a response to treatment, such as clinical notes, laboratory tests, pertinent pathology reports, or imaging studies.

    • Include current clinical and diagnostic information supporting treatment response.

    Unsupported block type: documentation

    Denial Risk

    Accepted Coverage Basis Required

    Authorization for the regimen may be denied when the requested single agent or regimen lacks an accepted coverage basis under this policy.

    • FDA-approved indication
    • NCCN category I or IIA recommendation
    • Applicable HMSA Criteria Exception policy for Commercial and Quest members or Off-Label Drug Use policy for Medicare Part B
    Denial Risk

    Benefit Exclusions and Contract Terms

    Coverage remains subject to the member’s benefit exclusions and contract language. If the policy guidelines conflict with the member contract, the contract language controls.

    • Confirm that the member has no exclusion for the prescribed therapy.
    • Apply the applicable member contract when determining coverage.
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied when the submitted documentation or objective measures do not demonstrate ongoing treatment benefit or show progression of disease.

    • Provide a current oncology assessment of response.
    • Include current imaging and other objective measures for comparison with prior results.
    Denial Risk

    Dose Exceeds Applicable Limits

    Approvals may be limited when the requested dose exceeds applicable dosing standards. Apply the limits established by FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

    • Verify the requested dose against FDA-approved labeling.
    • Check applicable accepted compendia and evidence-based practice guideline limits.